Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease

Stopped early · Phase 2

Conditions studied: Lymphoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory Hodgkin's disease.

Key facts

Study ID

NCT00005595

Run by

Northwestern University

People needed

2

Starts

2000-06-01

Expected to finish

2002-04-01

Last updated by the study team

2012-06-11

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Robert H. Lurie Comprehensive Cancer Center, Northwestern University — Chicago, Illinois, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.